The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab) on August 14, 2023. This approval, identified as BLA 125514 S-135, was specifically for an efficacy-related indication, expanding the drug's previously approved uses.
Background
Pembrolizumab (Keytruda), developed by MERCK SHARP DOHME, is a widely recognized programmed death receptor-1 (PD-1) blocking antibody, a type of immunotherapy used in various cancers. This supplemental approval specifically addresses an efficacy update, indicating that new clinical data has demonstrated its effectiveness for an additional or modified indication, thereby expanding its established therapeutic profile.
What this means
The FDA's supplemental approval for Keytruda (pembrolizumab) based on efficacy data confirms that new clinical evidence supports its benefits for an expanded or refined indication. This decision provides clinicians with an updated prescribing label, potentially enabling the use of pembrolizumab in a broader patient population or for a new disease setting where its effectiveness has now been formally recognized. For patients and advocates, this represents a potential new treatment option, while researchers will likely analyze the underlying data that led to this regulatory update.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval was announced on August 14, 2023, and details are publicly accessible via the FDA's Drugs@FDA database at accessdata.fda.gov, under application number BLA125514.